Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Non-Current Deffered Revenue: 2015-2024

Historic Non-Current Deffered Revenue for Editas Medicine (EDIT) over the last 10 years, with Dec 2024 value amounting to $54.2 million.

  • Editas Medicine's Non-Current Deffered Revenue changed negligibly% to $54.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $54.2 million, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $54.2 million for FY2024, which is 10.65% down from last year.
  • Per Editas Medicine's latest filing, its Non-Current Deffered Revenue stood at $54.2 million for FY2024, which was down 10.65% from $60.7 million recorded in FY2023.
  • Editas Medicine's 5-year Non-Current Deffered Revenue high stood at $74.0 million for FY2020, and its period low was $54.2 million during FY2024.
  • In the last 3 years, Editas Medicine's Non-Current Deffered Revenue had a median value of $60.7 million in 2023 and averaged $58.5 million.
  • Data for Editas Medicine's Non-Current Deffered Revenue shows a maximum YoY crashed of 54.67% (in 2020) over the last 5 years.
  • Editas Medicine's Non-Current Deffered Revenue (Yearly) stood at $74.0 million in 2020, then dropped by 17.70% to $60.9 million in 2021, then decreased by 0.36% to $60.7 million in 2022, then remained steady at $60.7 million in 2023, then dropped by 10.65% to $54.2 million in 2024.